Lexicon Pharmaceuticals | LXRX - Koszty Sprzedaży I Administracji





Koszty Sprzedaży I Administracji Zmiana Data
Abbott USD 3.6B 330M 2026-06
Acadia Pharmaceuticals USD 148.57M 12.22M 2026-06
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Akebia Therapeutics USD 23.53M 3.19M 2025-12
Alnylam Pharmaceuticals USD 347.92M 65.41M 2026-06
AstraZeneca USD 5.8B 735M 2026-06
BioMarin Pharmaceutical USD 395.55M 137.27M 2026-06
Coherus Biosciences USD 15M 6.26M 2025-12
Eli Lilly USD 3.43B 496M 2026-06
Halozyme Therapeutics USD 57M 10.71M 2026-06
Illumina USD 273M 1000K 2026-06
Insmed USD 247.47M 208K 2026-06
Ironwood Pharmaceuticals USD 33.33M 2.78M 2024-12
J&J USD 6.25B 168M 2026-09
Lexicon Pharmaceuticals USD 3.98M 195K 2025-12
MacroGenics USD 9.71M 1.77M 2026-03
MannKind USD 58.3M 4.22M 2026-06
Merck USD 2.89B 219M 2026-06
Moderna USD 216M 43M 2026-06
Novartis USD 3.24B 101M 2026-06
PTC Therapeutics USD 73.89M 13.31M 2026-03
Puma Biotechnology USD 16.82M 8.15M 2024-09
Sarepta Therapeutics USD 107.6M 53.57M 2026-06
Thermo Fisher Scientific USD 1.91B 111M 2026-06
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
United Therapeutics USD 206.7M 50.1M 2026-06
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12